|
|
5858 Horton Street, Suite 550
Emeryville, CA 94608 USA
phone:(510) 420-6700
fax:
|
|
| Symbol |
|
| Exchange |
|
| Founded |
0 |
| Employees |
|
|
|
| www.tethysbio.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Personalized predictive medicine for chronic conditions such as diabetes. |
|
| Management |
| Mickey S. Urdea, Co-Founder, Chairman and Chief Executive Officer; Michael P. McKenna, Chief Scientific Officer; R. Michael Richey, President; Steven M. Watkins, Chief Technology Officer; Mohan S. Iyer, Chief Business Officer |
| |
|
|
|
|
|
| Keywords |
| personalized medicine, predictive medicine, diabetes, |
|
|
|
| Description |
|
Tethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers — biomarkers — that provide a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes.
By developing new tests that use protein and other bloodborne biomarkers to identify people at high risk for devastating and preventable diseases, we can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers give a snapshot of an individual's current risk, which may be modifiable. Our goal is to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Our research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk.
The company has become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: Biomarkers. The company believes there is a large unmet need in both the discovery of potentially important biomarkers and the eventual use of them in routine clinical practice for many significant diseases.
Tethys Bioscience has built expertise, created significant intellectual property, and is executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. Tethys is focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
